BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

26 related articles for article (PubMed ID: 15372482)

  • 21. Tumor burden in Hodgkin's lymphoma can be reliably estimated from a few staging parameters.
    Gobbi PG; Bergonzi M; Bassi E; Merli F; Coriani C; Stelitano C; Iannitto E; Federico M
    Oncol Rep; 2012 Sep; 28(3):815-20. PubMed ID: 22752083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma.
    Gobbi PG; Valentino F; Bassi E; Coriani C; Merli F; Bonfante V; Marchianò A; Gallamini A; Bolis S; Stelitano C; Levis A; Federico M; Angrilli F; Di Giulio G; Corazza GR
    Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):396-402. PubMed ID: 21729691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy.
    Gobbi PG; Bassi E; Bergonzi M; Merli F; Coriani C; Iannitto E; Luminari S; Polimeno G; Federico M
    Hematol Oncol; 2012 Dec; 30(4):194-9. PubMed ID: 22271092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma.
    Gobbi PG; Broglia C; Di Giulio G; Mantelli M; Anselmo P; Merli F; Zinzani PL; Rossi G; Callea V; Iannitto E; Paulli M; Garioni L; Ascari E
    Cancer; 2004 Oct; 101(8):1824-34. PubMed ID: 15372482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors including clinical markers.
    Glimelius B
    Cancer Treat Res; 1989; 41():89-96. PubMed ID: 2577091
    [No Abstract]   [Full Text] [Related]  

  • 26.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.